Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Landos Biopharma stock | $10.98

Learn how to easily invest in Landos Biopharma stock.

Landos Biopharma, Inc
+$0.37 (+3.37%)

Landos Biopharma, Inc is a biotechnology business based in the US. Landos Biopharma shares (LABP) are listed on the NASDAQ and all prices are listed in US Dollars. Landos Biopharma employs 33 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Landos Biopharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LABP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Landos Biopharma stock price (NASDAQ: LABP)

Use our graph to track the performance of LABP stocks over time.

Landos Biopharma shares at a glance

Information last updated 2021-07-28.
Latest market close$10.98
52-week range$8.82 - $16.99
50-day moving average $11.27
200-day moving average $11.71
Wall St. target price$28.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Landos Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Landos Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Landos Biopharma price performance over time

Historical closes compared with the close of $10.98 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) -1.26%
3 months (2021-04-30) -0.36%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Landos Biopharma financials

Gross profit TTM $0
Return on assets TTM -28.68%
Return on equity TTM -45.97%
Profit margin 0%
Book value $2.54
Market capitalisation $454.9 million

TTM: trailing 12 months

Shorting Landos Biopharma shares

There are currently 512,209 Landos Biopharma shares held short by investors – that's known as Landos Biopharma's "short interest". This figure is 3.5% down from 530,866 last month.

There are a few different ways that this level of interest in shorting Landos Biopharma shares can be evaluated.

Landos Biopharma's "short interest ratio" (SIR)

Landos Biopharma's "short interest ratio" (SIR) is the quantity of Landos Biopharma shares currently shorted divided by the average quantity of Landos Biopharma shares traded daily (recently around 42970.553691275). Landos Biopharma's SIR currently stands at 11.92. In other words for every 100,000 Landos Biopharma shares traded daily on the market, roughly 11920 shares are currently held short.

To gain some more context, you can compare Landos Biopharma's short interest ratio against those of similar companies.

However Landos Biopharma's short interest can also be evaluated against the total number of Landos Biopharma shares, or, against the total number of tradable Landos Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Landos Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Landos Biopharma shares in existence, roughly 10 shares are currently held short) or 0.1091% of the tradable shares (for every 100,000 tradable Landos Biopharma shares, roughly 109 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Landos Biopharma.

Find out more about how you can short Landos Biopharma stock.

Landos Biopharma share dividends

We're not expecting Landos Biopharma to pay a dividend over the next 12 months.

Landos Biopharma overview

Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. .

Frequently asked questions

What percentage of Landos Biopharma is owned by insiders or institutions?
Currently 37.719% of Landos Biopharma shares are held by insiders and 65.689% by institutions.
How many people work for Landos Biopharma?
Latest data suggests 33 work at Landos Biopharma.
When does the fiscal year end for Landos Biopharma?
Landos Biopharma's fiscal year ends in December.
Where is Landos Biopharma based?
Landos Biopharma's address is: 1800 Kraft Drive, Blacksburg, VA, United States, 24060-6370

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site